Literature DB >> 1528079

Human pharmacology of a low-molecular-weight heparin (Alfa-LMWH): an update.

A G Dettori1, M Babbini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1528079     DOI： 10.1002/med.2610120404

Source DB:  PubMed          Journal:  Med Res Rev        ISSN： 0198-6325            Impact factor:   12.944


× No keyword cloud information.
  4 in total

1.  Role of parnaparin in atherosclerosis.

Authors:  Francesca Bonomini; Samanta Taurone; Pierpaolo Parnigotto; Loris Zamai; Luigi F Rodella; Marco Artico; Rita Rezzani
Journal:  Int J Exp Pathol       Date:  2017-02-16       Impact factor: 1.925

Review 2.  Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders.

Authors:  J E Frampton; D Faulds
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

Review 3.  Parnaparin : a review of its use in the management of venous thromboembolism, chronic venous disease and other vascular disorders.

Authors:  Kate McKeage; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 4.  Update on the clinical use of the low-molecular-weight heparin, parnaparin.

Authors:  Giuseppe Camporese; Enrico Bernardi; Franco Noventa
Journal:  Vasc Health Risk Manag       Date:  2009-10-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.